background: Bcl2 is known to belong to a family of apoptosis regulatory gene
products that may be death antagonist eg (bcl- 2, bcl-xl , mcl –l) or death
agonist ex (bax , bak , bcl -xs , bad) , The bcl- 2 oncoprotein inhibits apoptosis
and is expressed by many tumors including carcinoma such as breast ,cervix and head
and neck .
Aims to identify bcl-2 oncogene product expression of oral carcinoma and its
correlation to clinical features (exophytic , endophytic and mixed type) of oral
carcinoma
Patients and methods Twenty four patients were gathered , 20 patients had
squamous cell carcinoma and four patients with adenoid cystic carcinoma . Paraffin
blocks were obtained of the study group , specimens of follicular lymphoma paraffin
blocks were obtained from pathology department at teaching laboratory of medical
city . Normal oral mucosa were obtained from healthy patients who had undergone
routine oral surgery following informed consent of the patients .
Immunohistochemical procedure of Bcl2 protein were applied .
Results our study showed that 11 cases of the exophytic type of oral carcinoma
represented a positive bcl2 expression , 4 cases of the endophytic (ulcerative type)
showed a positive immunoreactivity with bcl2 antibodies and 3 cases of mixed type
(exophytic type and endophytic) showed a positive bcl2 expression . Statistical
analysis showed non significant relationship between clinical features (exophytic ,
endophytic , Mixed type) and bcl2 expression in oral carcinoma .
Conclusion :- bcl-2 expression in normal oral mucosa and oral carcinoma ,bcl-2
immunoreactivity was more correlated to mixed type , exophytic and rarely to
endophytic oral carcinoma but all didn't reach a statistical significance .
Keywords ,anti apoptotic gene product , bcl2 expression , oral carcinoma. |